We help scientific teams turn research into approved products.
Clementis is a founder-led consultancy for companies, universities and investors working in nanotechnology, nanomedicine, biomaterials and functional products. We assess what a programme has shown, what it still needs, and the route to regulatory approval and market.
Founded by Dr. Velaphi Thipe, chemist, MBA in life-science innovation, and principal inventor of an antimicrobial medical device approved by Brazil's health regulator, ANVISA.
Where programmes stall
Most promising results never become products, and the cause is rarely the science itself. Programmes stall when the evidence does not answer the questions a regulator or investor will ask, when the regulatory route is chosen too late, or when a process that works at the bench cannot be made consistently at scale.
Each of these problems is far cheaper to find early than late.
-
Evidence
Results that convince the lab but not a reviewer: a mechanism that is inferred rather than shown, a structure–activity relationship that has not been optimised, a dose–response that was never established.
-
Regulatory route
The same product can be a device, a drug, a cosmetic or a supplement depending on the market. The classification determines which studies, documents and reviews are required.
-
Scale-up
Nanomaterials and complex formulations often behave differently at pilot scale. A product that cannot be made consistently cannot be registered.
What we do
Engagements range from a single audit to a full programme. Most combine two or three of these areas.
-
Strategy and preclinical planning
A preclinical roadmap, structure–activity relationship work, and mechanism-of-action evidence that stands up to scientific and investor review.
-
Market intelligence
Market analysis and a target product profile, so development is aimed at a position the product can defend.
-
Programme audit and risk
A review of what is proven and what is missing, a risk register, and clear go/no-go decisions at each stage.
-
Clinical and regulatory planning
Evidence planning and regulatory route mapping for your lead markets.
-
IP and partnerships
IP landscape and freedom-to-operate review, and introductions to universities, contract research organisations and manufacturers.
We work mainly in nanotechnology and nanomedicine, translational oncology and molecular imaging, antimicrobial and functional biomaterials, green chemistry, and evidence-based nutraceuticals.
Services in detailHow an engagement runs
-
Discover
We map the science, the IP position and the market, and separate what has been shown from what has been assumed.
-
Audit
We assess the programme against readiness criteria, build the risk register and identify the gaps that must close first.
-
Decide
Each stage ends with a go/no-go recommendation and the reasoning behind it.
-
Prepare for market
We set the regulatory route and target product profile, and coordinate the partners and filings that follow.
Selected work
Carried out by the founder before Clementis was established.
-
Antimicrobial respiratory filter, Brazil
Principal inventor of the YouFilter Ag® filter, developed with ScavMedical. The device is approved by ANVISA and has been deployed in hospitals during respiratory procedures.
-
Ketone encapsulation, United States
A research collaboration with Tecton Life Group on encapsulating ketones using green nanotechnology, published in 2026 and the subject of a pending US patent application.
-
Nano-Ayurvedic immunotherapies, India
Research with Kadamba Nano that contributed to immunotherapies approved by India's AYUSH regulatory authority.
Founder
Dr. Velaphi Thipe
Founder and principal
A chemist and nanomedicine researcher with an MBA in life-science innovation. Dr. Thipe holds a PhD in Chemistry from the University of Missouri, studied there as a Fulbright Scholar, and was a senior postdoctoral research fellow in Radiology at its School of Medicine. The research covers green nanotechnology, cancer-targeted nanomedicine and molecular imaging, with more than 40 publications and pending patent applications in Brazil and the United States.
About the firmStart with a conversation
Write to us with a few lines about your programme and its stage. Dr. Thipe reads every enquiry and replies within two business days, usually suggesting a free 30-minute discovery call.